Realm Therapeutics plc, formerly PuriCore plc, is a biopharmaceutical company. The Company is focused on leveraging its immunomodulatory technology to protect and improve the health of adults and children. The Company has initiated drug development programs based on its hypochlorous acid technology. The Company is engaged in the development of small molecule therapies with potential application for the treatment of diseases in a number of therapeutic areas, and an initial focus in dermatology and ophthalmology. The Company has developed proprietary formulations of its technology, with anti-inflammatory and immunomodulatory benefits. Its pipeline of products include PR013 and PR022, which are in Phase I. PR013 is indicated for allergic conjunctivitis and PR022 is indicated for atopic dermatitis. Realm Therapeutics, Inc. is a subsidiary of the Company.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: N/A
- Symbol: LON:PURI
- CUSIP: N/A
- Web: www.realmtx.com
- 52 Week Range: GBX 16.90 - GBX 31.40
- Trailing P/E Ratio:
- P/E Growth:
- Net Margins: -902.53%
- Return on Equity: -49.39%
- Return on Assets: -41.39%
- Average Volume: 32,220 shs.
Frequently Asked Questions for Realm Therapeutics PLC (LON:PURI)
What is Realm Therapeutics PLC's stock symbol?
Realm Therapeutics PLC trades on the London Stock Exchange (LON) under the ticker symbol "PURI."
When will Realm Therapeutics PLC make its next earnings announcement?
Who are some of Realm Therapeutics PLC's key competitors?
Some companies that are related to Realm Therapeutics PLC include Incyte Corporation (INCY), Quintiles Transitional Holdings (Q), Alnylam Pharmaceuticals (ALNY), Alkermes PLC (ALKS), Qiagen N.V. (QGEN), Seattle Genetics (SGEN), Ionis Pharmaceuticals (IONS), Icon Plc (ICLR), United Therapeutics (UTHR), Charles River Laboratories International (CRL), Exact Sciences Corporation (EXAS), PRA Health Sciences (PRAH), Galapagos NV (GLPG), Bio-Techne Corp (TECH), PAREXEL International Corporation (PRXL), ACADIA Pharmaceuticals (ACAD), WuXi PharmaTech (Cayman) (WX) and Portola Pharmaceuticals (PTLA).
Who are Realm Therapeutics PLC's key executives?
Realm Therapeutics PLC's management team includes the folowing people:
- John Alex Martin, Chief Executive Officer, Executive Director
- Marella Thorell, Chief Financial Officer, Finance Director, Chief Operating Officer, Executive Director, Company Secretary
- Charles A. E. Spicer, Non-Executive Chairman
- Ivan Philip Gergel M.D., Non-Executive Director
- Balkrishan Gill, Non-Executive Director of the Board
- Matthew C. P. Hammond, Non-Executive Director
- Daniel Hegglin, Non-Executive Director
How do I buy Realm Therapeutics PLC stock?
Shares of Realm Therapeutics PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Realm Therapeutics PLC's stock price today?
MarketBeat Community Rating for Realm Therapeutics PLC (LON PURI)MarketBeat's community ratings are surveys of what our community members think about Realm Therapeutics PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Realm Therapeutics PLC stock can currently be purchased for approximately GBX 28.75.
Consensus Ratings for Realm Therapeutics PLC (LON:PURI) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Realm Therapeutics PLC (LON:PURI)
(Data available from 8/23/2015 forward)
|9/20/2016||N+1 Singer||Reiterated Rating||Corporate|
Earnings History for Realm Therapeutics PLC (LON:PURI)Earnings History by Quarter for Realm Therapeutics PLC (LON PURI)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Realm Therapeutics PLC (LON:PURI)
Current Year EPS Consensus Estimate: $0.09 EPS
Dividend History for Realm Therapeutics PLC (LON:PURI)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Realm Therapeutics PLC (LON:PURI)Insider Trades by Quarter for Realm Therapeutics PLC (LON:PURI)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/22/2016||Charles Spicer||Insider||Buy||17,482||GBX 29||£5,069.78|
|10/14/2015||Hegglin ,Daniel||Insider||Buy||500,000||GBX 18||£90,000|
|4/1/2015||Charles Spicer||Insider||Buy||50,610||GBX 32||£16,195.20|
Headline Trends for Realm Therapeutics PLC (LON:PURI)
Latest Headlines for Realm Therapeutics PLC (LON:PURI)
Realm Therapeutics PLC (PURI) Chart for Wednesday, August, 23, 2017